#lymphocyticLeukemia
LightNews LightNews
ascocancer.bsky.social
Tomorrow's #ASCO25 Education Session on "When and How Long to Treat Chronic #LymphocyticLeukemia" has an accompanying #ASCOEdBook paper. Take a look: ascopubs.org/doi/10.1200/...
#lymsm
May 30, 2025 at 7:56 PM
hematologyadvisor.bsky.social
A review of #machinelearning models developed to support the management of chronic #lymphocyticLeukemia have demonstrated positive outcomes, including accurate diagnosis and improved work flow.

https://bit.ly/3HQxIqV

#lymsm #leusm
Machine Learning Models May Improve CLL Diagnosis and Management
Researchers determined machine learning models developed to support the management of CLL have demonstrated positive outcomes.
bit.ly
September 18, 2025 at 7:30 PM
hematologyadvisor.bsky.social
Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournal.bsky.social.

https://bit.ly/3N3LYyQ

#CLL #leusm
Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL
Researchers determined venetoclax-obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated CLL.
bit.ly
March 5, 2026 at 4:52 AM
hematologyadvisor.bsky.social
Patients with chronic #lymphocyticLeukemia are at increased risk for secondary malignancies, which often have aggressive courses and poor outcomes. Published in @cureusmedical.bsky.social and @rarediseaseadvisor.bsky.social.

https://bit.ly/4gjUJPC

#leusm #CLL
Secondary Malignancies in CLL Highlight the Need for Vigilant Surveillance
CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.
bit.ly
September 21, 2025 at 7:59 PM
hematologyadvisor.bsky.social
A prognostic risk score based on fatty acid metabolism gene expression revealed distinct immune phenotypic differences and implicated fatty acid oxidation in chronic #lymphocyticLeukemia progression. Published in @rarediseaseadvisor.bsky.social.

bit.ly/3GE6Qt4

#CLL
Fatty Acid Oxidation Inhibition Enhanced PI3K Inhibitor Efficacy in CLL
A 3-gene fatty acid metabolism score (LPL, SOCS3, CNR1) predicted prognosis in CLL and correlated with immune phenotypes.
bit.ly
May 12, 2025 at 3:55 PM
oncologynurseadv.bsky.social
The Clinical Frailty Scale was associated with early treatment discontinuation among older adults with chronic #lymphocyticLeukemia treated with zanubrutinib. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4q7Shix

#CLL #leusm
Frailty Scale May Predict Treatment Cessation in Older Patients With CLL - Oncology Nurse Advisor
After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.
bit.ly
February 4, 2026 at 5:54 PM
oncologynurseadv.bsky.social
Use of a pharmacist-led clinic for administering venetoclax was considered safe and effective in a study including patients with chronic #lymphocyticLeukemia that was led by a research team based in Edmonton, Alberta, Canada.

bit.ly/4k5NxHt

#CLL
Pharmacist-Led Clinic for Administering Venetoclax Safe, Effective for CLL - Oncology Nurse Advisor
Researchers sought to determine whether a pharmacist-led clinic for administering venetoclax would be effective for patients with CLL.
bit.ly
May 12, 2025 at 5:49 PM
hematologyadvisor.bsky.social
Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4cvVQvQ

#lymsm #leusm #CLL
Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL - Oncology Nurse Advisor
Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.
bit.ly
March 6, 2026 at 3:22 AM
hematologyadvisor.bsky.social
Live cell imaging-derived phenotypes reliably forecasted clinically relevant heterogeneity in chronic #lymphocyticLeukemia and delineated patient cohorts likely to respond to ruxolitinib, venetoclax, or their combination. Published in @cp-iscience.bsky.social.

https://bit.ly/3Z0pbq4

#CLL #leusm
Live Cell Phenotyping Stratifies CLL and Predicts Response to Targeted Therapy
Machine-learning analysis of untreated CLL samples identified 5 stable patient clusters associated with distinct therapeutic sensitivities.
bit.ly
January 10, 2026 at 7:18 PM
hematologyadvisor.bsky.social
Patients with chronic #lymphocyticLeukemia who discontinued covalent BTKi and later required BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap. From @rarediseaseadvisor.bsky.social.

https://bit.ly/3MX8zg6

#CLL #leusm
Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL
Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.
bit.ly
December 25, 2025 at 3:55 PM
hematologyadvisor.bsky.social
Granulomatous acute interstitial nephritis is a rare but important cause of renal dysfunction in patients with chronic #lymphocyticLeukemia. From @rarediseaseadvisor.bsky.social.

https://bit.ly/49u4fym

#CLL #leusm
Granulomatous Acute Interstitial Nephritis Can Cause Renal Dysfunction in CLL
The patient initiated treatment with zanubrutinib and high-dose corticosteroids, resulting in partial improvement in renal function.
bit.ly
November 22, 2025 at 8:49 PM
cancertherapyadv.bsky.social
Significant treatment options with targeted therapies are changing the management of chronic #lymphocyticLeukemia. Presented at #ASH25 with Adam Kittai, MD of Icahn Mount Sinai.

https://bit.ly/44GOoZZ

#CLL #leusm
ASH 2025: Refining the Modern Management of CLL in the Era of Targeted Therapies
Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.
bit.ly
December 22, 2025 at 7:42 PM